Cas9 Stable Cell Line - HSC3

The HSC3 cell line, derived from human oral squamous cell carcinoma, is an important model for studying head and neck tumors. The Cas9 Stable Cell Line - HSC3 is constructed by stably integrating the CRISPR-associated protein 9 (Cas9) endonuclease into HSC3 cells. This gene modification allows for precise targeted genome editing without transient transfection. The cell line maintains stable Cas9 expression even under antibiotic selection, ensuring consistent editing efficiency after passage. HSC3 cells exhibit typical epithelial cell morphology and retain key cancer characteristics such as rapid proliferation and invasion, making them ideal for studying oral cancer biology.

The Cas9 Stable Cell Line - HSC3 revolutionizes functional genomics research, enabling high-throughput gene knockout screening to identify oncogenes, tumor suppressor genes, and drug resistance mechanisms specific to head and neck malignancies. Researchers use this cell line to construct cancer-related mutation models, validate therapeutic targets, and study signaling pathways such as EGFR and PI3K/AKT. In drug development, this cell line can be used to rapidly evaluate the efficacy of CRISPR-based therapies or compounds through combination gene editing technologies. Furthermore, it supports synthetic lethality studies for precision oncology and the study of interactions within the tumor microenvironment. The adaptability of the Cas9-HSC3 cell line is also evident in the construction of patient-derived xenograft (PDX) models and the exploration of immunotherapy resistance, providing a multifunctional platform for basic research and translational applications in oncology.